Beam Therapeutics also said the study met all secondary endpoints and expects to submit a U.S. biologics license application as early as year-end 2026.
Written by GetSignal with AI from SEC filings and the company’s own press releases; each article links to its source. Not investment advice.
Earnings6 reported quarters · next on Feb 23, 2027
Earnings
Quarter
EPS
EPS expected
Revenue
Revenue expected
Result
Q3 FY2026reported Nov 3, 2026
-$1.28
-$1.15
$307K
$8.8M
EPS miss, GAAPRevenue miss
Q2 FY2026reported Aug 4, 2026
-$1.18
-$1.11
$490K
$16.4M
EPS miss, GAAPRevenue miss
Q1 FY2026reported May 7, 2026
-$0.91
-$0.87
$31.7M
$11.0M
EPS miss, GAAPRevenue beat
Q4 FY2025reported Feb 24, 2026
-$0.10
-$1.13
$114.1M
$11.7M
EPS beatRevenue beat
Q3 FY2025reported Nov 4, 2025
-$1.10
-$0.98
$9.7M
$13.2M
EPS miss, GAAPRevenue miss
Q2 FY2025reported Aug 5, 2025
-$1.00
-$1.04
$8.5M
$11.5M
EPS beat, GAAPRevenue miss
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
John Evans’s pay as CEO came to $5.8M for fiscal 2025.
Executive
Salary
Stock awards
Other
Total
John EvansCEO
$755K
$1.5M
$3.5M
$5.8M
Giuseppe Ciaramella, Ph.D.President
$668K
$684K
$1.8M
$3.2M
Amy Simon, M.D. CMO
$550K
$884K
$1.4M
$2.8M
Christine Bellon, Ph.D.CLO
$511K
$391K
$1.1M
$2.0M
Sravan K. EmanyCFO
$575K
$0
$722K
$1.3M
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing
13F filings13F positions as of Sep 30, 2026
Institutional holders
191 institutions reported Beam Therapeutics shares in 13F filings for Sep 30, 2026.
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Sep 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
3 of the fund managers in GetSignal’s fund directory list BEAM shares among the largest positions in their latest 13F, filed for Q3 2026. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.
One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.
Other Form 4 activity (7)
Insider
Event
Shares
Date
John M. EvansCEO
Option exercise
25,000
Oct 15, 2026
John M. EvansCEO
Option exercise
25,000
Oct 16, 2026
Giuseppe CiaramellaPresident
Gift
123,407
Sep 24, 2026
John M. EvansCEO
Option exercise
25,000
Jun 29, 2026
John M. EvansCEO
Option exercise
25,000
Jun 30, 2026
Giuseppe CiaramellaPresident
Option exercise
35,505
Jun 17, 2026
Christi ShawDirector
Stock award
19,676
Jun 3, 2026
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
On Form 4, code P is an open-market purchase and S an open-market sale; a sale marked scheduled was set up in advance under a Rule 10b5-1 plan. Awards, option exercises, tax withholding and gifts (A, M, F and G) are listed under Other Form 4 activity and never counted as either.
What the filings on BEAM show and how current they are.
Are insiders buying or selling BEAM?
Across the 9 most recent open-market filings shown here, 0 were purchases and 9 were sales. 7 were scheduled in advance under a Rule 10b5-1 plan.
How quickly are BEAM trades disclosed?
Insider filings on this page reached the public a median of 1 business day after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows.